Prospective Grant of Exclusive Patent License: Development and Commercialization of Peptides Promoting Lipid Efflux for the Treatment of Hypertriglyceridemia, With or Without Concomitant Metabolic Syndrome, 16405-16406 [2017-06546]
Download as PDF
Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices
discussion, and evaluation of
applications received in response to
‘‘Community Characteristics Associated
with Geographic Disparities in Diabetes
and Cardiometabolic Health’’, DP17–
001.
Contact Person for More Information:
Jaya Raman Ph.D., Scientific Review
Officer, CDC, 4770 Buford Highway,
Mailstop F80, Atlanta, Georgia 30341,
Telephone: (770) 488–6511, kva5@
cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–06536 Filed 4–3–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meetings
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Initial Review Group, Biological Aging
Review Committee.
Date: May 30–31, 2017.
Time: 2:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Torrance Marriott Redondo Beach,
3635 Fashion Way, Torrance, CA 90503.
Contact Person: Bita Nakhai, Ph.D.,
Scientific Review Branch, National Institute
on Aging, Gateway Bldg., 2C212, 7201
Wisconsin Avenue, Bethesda, MD 20814,
301–402–7701, nakhaib@nia.nih.gov.
VerDate Sep<11>2014
16:21 Apr 03, 2017
Jkt 241001
Name of Committee: National Institute on
Aging Initial Review Group, Neuroscience of
Aging Review Committee,
Date: June 1–2, 2017.
Time: 2:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Torrance Marriott Redondo Beach,
3635 Fashion Way, Torrance, CA 90503.
Contact Person: Jeannette L. Johnson,
Ph.D., Deputy Review Branch Chief, National
Institutes of Health, National Institute on
Aging, Gateway Building, Bethesda, MD
20892, 301–402–7705, johnsonj9@
nia.nih.gov.
Name of Committee: National Institute on
Aging Initial Review Group, Clinical Aging
Review Committee.
Date: June 1–2, 2017.
Time: 2:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Torrance Marriott Redondo Beach,
3635 Fashion Way, Torrance, CA 90503.
Contact Person: Alicja L. Markowska,
Ph.D., Dsc., National Institute on Aging,
National Institutes of Health, Gateway
Building 2C212, 7201 Wisconsin Avenue,
Bethesda, MD 20892, 301–496–9666,
markowsa@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
16405
Only written comments and/or
applications for a license which are
received by the NHLBI Office of
Technology Transfer and Development
on or before April 19, 2017 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
exclusive license should be directed to:
Cristina Thalhammer-Reyero, Ph.D.,
MBA, Senior Licensing and Patenting
Manager, NHLBI Office of Technology
Transfer and Development, 31 Center
Drive Room 4A29, MSC2479, Bethesda,
MD 20892–2479; Telephone: +1–301–
435–4507; Fax: +1–301–594–3080;
Email: thalhamc@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
following represents the intellectual
property to be licensed under the
prospective agreement:
U.S. Provisional Patent Application
Serial No. 61/045,213, filed 04/15/2008;
PCT Application No. PCT/US2009/
040560, filed 04/14/2009; U.S. Patent
Application Serial No.12/937,974,
issued as 8,936,787 on 01/20/2015;
Titled ‘‘Peptides Promoting Lipid
Efflux’’ (NIH Reference No. E–138–
Dated: March 29, 2017.
2008/0).
Melanie J. Pantoja,
With respect to persons who have an
obligation to assign their right, title and
Program Analyst, Office of Federal Advisory
Committee Policy.
interest to the Government of the United
States of America, the patent rights in
[FR Doc. 2017–06553 Filed 4–3–17; 8:45 am]
these inventions have been assigned to
BILLING CODE 4140–01–P
the Government of the United States of
America.
The prospective exclusive license
DEPARTMENT OF HEALTH AND
territory may be worldwide and the
HUMAN SERVICES
field of use may be limited to:
National Institutes of Health
‘‘Treatment of Hypertriglyceridemia,
with or without concomitant metabolic
Prospective Grant of Exclusive Patent
syndrome’’.
License: Development and
The invention pertains to
Commercialization of Peptides
compositions and methods of use of
Promoting Lipid Efflux for the
ApoC–II mimetic peptides with
Treatment of Hypertriglyceridemia,
multiple amphipathic alpha helical
With or Without Concomitant
domains that have the dual ability to
Metabolic Syndrome
promote lipid efflux from cells and
stimulate lipoprotein lipase activity,
AGENCY: National Institutes of Health,
without inducing toxicity. This notice is
HHS.
made in accordance with 35 U.S.C. 209
ACTION: Notice.
and 37 CFR part 404. The prospective
SUMMARY: The National Heart, Lung, and Exclusive Patent License will be royalty
Blood Institute (NHLBI), an institute of
bearing and may be granted unless
the National Institutes of Health; an
within fifteen (15) days from the date of
agency within the Department of Health this published notice, the NHLBI Office
and Human Services, is contemplating
of Technology Transfer and
the grant of an exclusive patent license
Development receives written evidence
to commercialize the invention(s)
and argument that establishes that the
embodied in the intellectual property
grant of the license would not be
estate stated in the Summary
consistent with the requirements of 35
Information section of this notice to
U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
Corvidia Therapeutics Inc. (Corvidia)
the prospective field of use that are
located in Waltham, MA and
timely filed in response to this notice
incorporated under the laws of
will be treated as objections to the grant
Delaware.
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
DATES:
E:\FR\FM\04APN1.SGM
04APN1
16406
Federal Register / Vol. 82, No. 63 / Tuesday, April 4, 2017 / Notices
of the contemplated Exclusive Patent
License. Comments and objections to
this notice submitted will not be made
available for public inspection and, to
the extent permitted by law, will not be
released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: March 21, 2017.
Cristina Thalhammer-Reyero,
Senior Licensing and Patenting Manager,
Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.
[FR Doc. 2017–06546 Filed 4–3–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-up
Exclusive Evaluation Option Patent
License: ‘‘The Development and Use of
Diazeniumdiolated and Hybrid
Diazeniumdiolated Compounds for the
Treatment of Ovarian Cancer in
Humans’’
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of a Start-up Exclusive Evaluation
Option License to practice the
inventions embodied in the Patents and
Patent Applications listed in the
Supplementary Information section of
this notice to Tar Meta Biosciences, Inc.
(‘‘TarMeta’’) located in King of Prussia,
PA, USA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before April 19, 2017 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
Start-up Exclusive Evaluation Option
License should be directed to: Kathleen
Higinbotham, Senior Technology
Transfer Manager, NCI Technology
Transfer Center, Riverside 5, Suite 400,
8490 Progress Dr., Frederick, MD 21701,
Telephone: (301)-624–8775; Facsimile:
(301)-631–3027 Email: higinbok@
mail.nih.gov.
SUPPLEMENTARY INFORMATION:
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
Intellectual Property
(1) E–025–2010/0 entitled ‘‘Nitric Oxidebased Cancer Therapeutic Agents For Lung
VerDate Sep<11>2014
16:21 Apr 03, 2017
Jkt 241001
Cancers With Elevated Levels Of Reactive
Oxygen Species (ROS) And/or Low Levels Of
Antioxidant Defense/DNA Repair
Mechanisms.’’
(a) United States Provisional Patent
Application No. 61/261,175 filed November
13, 2009;
(b) PCT Application No. PCT/US2010/
056446 filed November 12, 2010;
(c) United States Patent Application No.
13/509,431 filed June 01, 2012, US Patent
9,205,091 issued December 08, 2015;
(d) Australian Patent Application No.
2010319398 filed May 09, 2012;
(e) Canadian Patent Application No.
2,780,633 filed May 10, 2012;
(f) European Patent Application No.
10778814.3 filed May 14, 2012;
(2) E–220–2011/0 entitled ‘‘Hybrid
Diazeniumdiolated Compounds,
Pharmaceutical Compositions, And Method
Of Treating Cancer.’’
(a) United States Provisional Patent
Application No. 61/549,862, filed October 21,
2011;
(b) PCT Application No. PCT/US2012/
060785 filed October 18, 2012;
(c) United States Patent Application No.
14/352,096 filed April 16, 2014, US Patent
9,168,266 issued October 27, 2015;
(d) Australian Patent Application No.
2012326105 filed April 14, 2014;
(e) Canadian Patent Application No.
2,852,682 filed April 14, 2014;
(f) European Patent Application No.
12841601.3 filed April 14, 2014, European
Patent 2768824 issued December 07, 2016;
(i) German Patent 602012026435.7 issued
December 07, 2016;
(ii) French Patent 2768824 issued
December 07, 2016; and
(iii) UK Patent 2768824 issued December
07, 2016.
The patent rights in these inventions
have been assigned to the government of
the United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to ‘‘The
development and use of
diazeniumdiolated and hybrid
diazeniumdiolated compounds for the
treatment of ovarian cancer in humans.’’
The present inventions describe the
use of diazeniumdiolate-based nitric
oxide (NO)-releasing compounds
wherein the cancer cell has an elevated
level of reactive oxygen species (ROS),
as well as the use of hybrid prodrug
molecules that combine a
diazeniumdiolated compound and a
poly(ADP-ribose) polymerase (PARP)
inhibitor in cancer cells to produce
synergistic effects, whether alone or as
an adjuvant for other therapies. The
hybrid prodrug is expected to enhance
cytotoxicity by creating DNA damage
with NO and preventing its repair with
the PARP inhibitor. The prodrug and
the hybrid are activated by glutathione
S-transferase and are predicted to be
effective in cancers with reactive oxygen
species (ROS), both of which are
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
elevated in many cancers. In addition,
the prodrug and hybrid may have
synergy with therapeutics (such as
proteasome inhibitor bortezomib and
doxorubicin) which act through
generation of ROS. Taken together, these
features suggest that the prodrug and
hybrid may have therapeutic
applications in cancer patients whose
tumors include high levels of ROS.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective Start-up Exclusive
Evaluation Option License will be
royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Start-up Exclusive
Evaluation Option License Agreement.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: March 21, 2017.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2017–06545 Filed 4–3–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 82, Number 63 (Tuesday, April 4, 2017)]
[Notices]
[Pages 16405-16406]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-06546]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Development and
Commercialization of Peptides Promoting Lipid Efflux for the Treatment
of Hypertriglyceridemia, With or Without Concomitant Metabolic Syndrome
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Heart, Lung, and Blood Institute (NHLBI), an
institute of the National Institutes of Health; an agency within the
Department of Health and Human Services, is contemplating the grant of
an exclusive patent license to commercialize the invention(s) embodied
in the intellectual property estate stated in the Summary Information
section of this notice to Corvidia Therapeutics Inc. (Corvidia) located
in Waltham, MA and incorporated under the laws of Delaware.
DATES: Only written comments and/or applications for a license which
are received by the NHLBI Office of Technology Transfer and Development
on or before April 19, 2017 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated exclusive license should be
directed to: Cristina Thalhammer-Reyero, Ph.D., MBA, Senior Licensing
and Patenting Manager, NHLBI Office of Technology Transfer and
Development, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-
2479; Telephone: +1-301-435-4507; Fax: +1-301-594-3080; Email:
thalhamc@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The following represents the intellectual
property to be licensed under the prospective agreement:
U.S. Provisional Patent Application Serial No. 61/045,213, filed
04/15/2008; PCT Application No. PCT/US2009/040560, filed 04/14/2009;
U.S. Patent Application Serial No.12/937,974, issued as 8,936,787 on
01/20/2015; Titled ``Peptides Promoting Lipid Efflux'' (NIH Reference
No. E-138-2008/0).
With respect to persons who have an obligation to assign their
right, title and interest to the Government of the United States of
America, the patent rights in these inventions have been assigned to
the Government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to: ``Treatment of
Hypertriglyceridemia, with or without concomitant metabolic syndrome''.
The invention pertains to compositions and methods of use of ApoC-
II mimetic peptides with multiple amphipathic alpha helical domains
that have the dual ability to promote lipid efflux from cells and
stimulate lipoprotein lipase activity, without inducing toxicity. This
notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404.
The prospective Exclusive Patent License will be royalty bearing and
may be granted unless within fifteen (15) days from the date of this
published notice, the NHLBI Office of Technology Transfer and
Development receives written evidence and argument that establishes
that the grant of the license would not be consistent with the
requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are timely filed in response to this notice will be treated as
objections to the grant
[[Page 16406]]
of the contemplated Exclusive Patent License. Comments and objections
to this notice submitted will not be made available for public
inspection and, to the extent permitted by law, will not be released
under the Freedom of Information Act, 5 U.S.C. 552.
Dated: March 21, 2017.
Cristina Thalhammer-Reyero,
Senior Licensing and Patenting Manager, Office of Technology Transfer
and Development, National Heart, Lung, and Blood Institute.
[FR Doc. 2017-06546 Filed 4-3-17; 8:45 am]
BILLING CODE 4140-01-P